Kirkpatrickvelez6589
Tranexamic acid (TXA) is a novel treatment option for melasma; however, no consensus exists on its use. Staurosporine concentration This study evaluates the efficacy and safety of TXA for melasma.
A comprehensive literature review was conducted to search for randomized controlled trials comparing TXA alone, TXA as adjuvant to routine treatment and placebo. Changes in the Melasma Area Severity Index (MASI)/modified MASI (mMASI) between pre- and post-treatment and between a certain melasma treatment and TXA were the primary outcomes. Twenty-four trials comparing oral, topical or intradermal TXA with routine treatment were included in the meta-analysis.
The change in MASI/mMASI scores at 4 (MD, 3.58; 95% confidence interval (CI), 2.15-5.01), 8 (MD, 5.08; 95% CI, 3.34-6.81), 12 (MD, 4.89; 95% CI, 3.80-5.97) and 16 (MD, 6.55; 95% CI, 2.62-10.48) weeks after treatment was all less than the baseline scores, regardless of the delivery route. The reduction in the MASI/mMASI scores between TXA adjuvant and routine treatment at 4 (MD, -0.43; 95% CI, -0.79 to -0.08), 8 (MD, -0.81; 95% CI, -1.09 to -0.54), 12 (MD, -1.10; 95% CI, -1.78 to -0.43) and 16 (MD, -1.12; 95% CI, -1.51 to -0.74) weeks was significant. However, the superiority of TXA was not detected when the topical or intradermal route was adopted. No serious adverse events occurred with the use of TXA.
These results suggest that oral TXA is an available, effective and safe alternative treatment for melasma.
These results suggest that oral TXA is an available, effective and safe alternative treatment for melasma.
During a typical cardiac short scan, the heart can move several millimeters. As a result, the corresponding CT reconstructions may be corrupted by motion artifacts. Especially the assessment of small structures, such as the coronary arteries, is potentially impaired by the presence of these artifacts. In order to estimate and compensate for coronary artery motion, this manuscript proposes the deep partial angle-based motion compensation (Deep PAMoCo).
The basic principle of the Deep PAMoCo relies on the concept of partial angle reconstructions (PARs), that is, it divides the short scan data into several consecutive angular segments and reconstructs them separately. Subsequently, the PARs are deformed according to a motion vector field (MVF) such that they represent the same motion state and summed up to obtain the final motion-compensated reconstruction. However, in contrast to prior work that is based on the same principle, the Deep PAMoCo estimates and applies the MVF via a deep neural network to increase the computational performance as well as the quality of the motion compensated reconstructions.
Using simulated data, it could be demonstrated that the Deep PAMoCo is able to remove almost all motion artifacts independent of the contrast, the radius and the motion amplitude of the coronary artery. In any case, the average error of the CT values along the coronary artery is about 25HU while errors of up to 300HU can be observed if no correction is applied. Similar results were obtained for clinical cardiac CT scans where the Deep PAMoCo clearly outperforms state-of-the-art coronary artery motion compensation approaches in terms of processing time as well as accuracy.
The Deep PAMoCo provides an efficient approach to increase the diagnostic value of cardiac CT scans even if they are highly corrupted by motion.
The Deep PAMoCo provides an efficient approach to increase the diagnostic value of cardiac CT scans even if they are highly corrupted by motion.Due to its aggressive and invasive nature glioblastoma (GBM), the most common and aggressive primary brain tumour in adults, remains almost invariably lethal. Significant advances in the last several years have elucidated much of the molecular and genetic complexities of GBM. However, GBM exhibits a vast genetic variation and a wide diversity of phenotypes that have complicated the development of effective therapeutic strategies. This complex pathogenesis makes necessary the development of experimental models that could be used to further understand the disease, and also to provide a more realistic testing ground for potential therapies. In this report, we describe the process of transformation of primary mouse embryo astrocytes into immortalized cultures with neural stem cell characteristics, that are able to generate GBM when injected into the brain of C57BL/6 mice, or heterotopic tumours when injected IV. Overall, our results show that oncogenic transformation is the fate of NSC if cultured for long periods in vitro. In addition, as no additional hit is necessary to induce the oncogenic transformation, our model may be used to investigate the pathogenesis of gliomagenesis and to test the effectiveness of different drugs throughout the natural history of GBM.
A multi-scale investigation of the biological properties of gadolinium neutron capture (GdNC) therapy with applications in particle therapy is conducted using the TOPAS Monte Carlo (MC) simulation code. The simulation results are used to quantify the amount of gadolinium dose enhancement produced as a result of the secondary neutron production from proton therapy scaled by measured data.
MC modeling was performed using the radiobiology extension TOol for PArticle Simulation TOPAS-nBio MC simulation code to study the radiobiological effects produced from GdNC on a segment of DNA, a spherical cellular model, and from the modeling of previous experimental measurements. The average RBE values were calculated from two methods, microdosimetric kinematic (MK) and biological weighting r(y) within a 2nm DNA segment for GdNC. The single-strand breaks (SSBs) and double-strand breaks (DSBs) were calculated from within the nucleus of a 20µm diameter, spherical cell model. From a previous experimental proton therapy merapy. Moreover, alternative neutron sources, such as, a compact deuterium-tritium (D-T) neutron generator, a "high yield" deuterium-deuterium (D-D) generator, or an industrial strength (100 mg) 252 Cf source were investigated, with the 252 Cf source the most likely to be capable of producing enough neutrons for 1 Gy of localized GdNC absolute dose within a reasonable treatment time.
